Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori
Received 20 November 2019
Accepted for publication 7 January 2020
Published 22 January 2020 Volume 2020:13 Pages 25—33
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. Wing-Kin Syn
Hassan Tariq, 1, 2 Harish Patel, 1, 2 Muhammad Umar Kamal, 1 Naeem Abbas, 1, 2 Muhammad Ameen, 1 Sara Azam, 1 Kishore Kumar, 1, 2 Madhavi Ravi, 1, 2 Vamshidhar Vootla, 1, 2 Danial Shaikh, 1, 2 Vamsi Amanchi, 1 Ali N Hussain, 3 Jasbir Makker 1, 2
1Department of Medicine, BronxCare Health System, Bronx, NY 10457, USA; 2Division of Gastroenterology, BronxCare Health System, Bronx, NY 10457, USA; 3Baruch College, City University of New York (CUNY), New York, NY 10010, USA
Correspondence: Muhammad Umar Kamal
BronxCare Health System, 1650 Selwyn Ave, Suite #10C, Bronx, NY 10457, USA
Tel +1 718-960-1234
Fax +1 718-960-2055
Background: Helicobacter pylori is a common cause of gastritis, peptic ulcer disease, and non-ulcer dyspepsia, and is also associated with gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma. Despite being known about for more than 30 years, finding an effective therapeutic strategy against it remains a challenge.
Aim: There are no US studies evaluating the efficacy of a Levofloxacin based therapy for H. pylori infection. We here intend to study the efficacy of Levofloxacin based triple antibiotic regimen as compared to Clarithromycin based triple therapy and Bismuth based quadruple therapy in our patient population.
Methods: This is a retrospective single center observational study. Patients with Helicobacter pylori infection who underwent treatment for H. pylori with one of the three therapies, i.e. Clarithromycin triple, Bismuth Quadruple or Levofloxacin triple, were included in the study and the eradication rates were compared. The confirmation of the H. pylori was done 4 weeks after the completion of anti-microbial therapy.
Results: A total of 177 individuals underwent the H. pylori treatment in our retrospective review. Of these, 54% (n=97) of patients were treated with Clarithromycin based triple therapy (Group 1), 35% (n=63) were treated with Levofloxacin based regimen (Group 2), and the remaining 11% (n=17) were treated with Bismuth based quadruple therapy (Group 3). The eradication rates were significantly higher in patients treated with Clarithromycin based triple therapy as compared to Levofloxacin based triple therapy and Bismuth quadruple therapy (78.3% vs 49.2% vs 41.1% P=0.001).
Conclusion: In conclusion, our study shows significantly lower eradication rates with Levofloxacin triple therapy among a selected US population. Thus, it may not be a good first-line therapy among this US population and the Clarithromycin based regimen may still be used successfully.
Keywords: Helicobacter pylori, clarithromycin, levofloxacin, quadruple therapy, peptic ulcer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]